Abridge Secures $250M in Series D Funding, Expands AI-Powered Medical Documentation Solutions

Abridge, a leader in ambient AI technology for medical documentation, has raised $250 million in a Series D funding round, propelling its valuation to $2.75 billion. This significant investment comes as health systems across the United States increasingly adopt AI-powered tools to streamline clinical workflows and alleviate the documentation burden on healthcare professionals.

Rapid Adoption and Expansion

Abridge's AI-driven platform has seen remarkable growth, with deployments now spanning more than 100 health systems. Recent adopters include prestigious institutions such as Akron Children's, Endeavor Health, Inova, Memorial Sloan Kettering Cancer Center, and CVS Health-owned Oak Street Health. The company has also announced enterprise-wide implementations at Duke Health, Johns Hopkins, Mayo Clinic, and UNC Health within the past two months, representing tens of thousands of clinicians utilizing the technology.

Dr. Bonnie Boles, Chief Medical Information Officer at Tanner Health, highlighted the platform's impact: "A busy primary care doctor reported that this is the first time in 30 years she is finishing her notes by the end of clinic. A surgeon told me that he used to spend 4-5 hours at the end of every day to finish documentation—now he's done in an hour."

New AI Capabilities and Financial Applications

Abridge has unveiled a new AI tool designed to streamline both clinical and financial workflows at the point of care. This innovative "contextual reasoning engine" aims to address challenges associated with incomplete clinical notes that often delay billing processes. By producing billable notes that support appropriate claims in real-time, the tool promises to enhance efficiency and reduce administrative bottlenecks.

Dr. Shiv Rao, Abridge's CEO and founder, emphasized the company's commitment to long-term partnerships with health systems: "We aspire to serve our health system partners for the decades to come. This investment supports that aspiration, as well as the core research and development that differentiates our approach."

Investment Details and Future Plans

The Series D funding round was co-led by Elad Gil and IVP, with participation from a roster of prominent investors including Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures (NVIDIA's venture capital arm), Redpoint Ventures, Spark Capital, and SV Angel.

Abridge plans to leverage this substantial investment to further develop its AI capabilities and fuel commercial growth, supporting broader applications of its technology across the healthcare sector. The funding follows a $150 million Series C round just a year ago, which was earmarked for research and development of foundation models.

As Abridge continues to innovate and expand its presence in the healthcare AI space, the company's growth trajectory underscores the increasing importance of artificial intelligence in addressing longstanding challenges in medical documentation and clinical workflows.